Loading…
Lobbying Spend
—
Filings
43
Firms Hired
2
Active Period
2017–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Land Management relating to Public Land Order No. 7917 for Withdrawal of Federal Lands; Cook, Lake, and Saint Louis Counties, MN.
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
H.J. Res. 140 (Congressional Review Act disapproval of Public Land Order (PLO) 7917) issued by the Biden Administration to withdraw more than 225,000 acres of the Superior National Forest from mineral development for 20 years
Client expense: — · Firm income: $25,000
Matched citations: H.J. Res. 140
Providing congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to "California State Motor Vehicle and Engine Pollution Control Standards; Advanced Clean Cars II; Waiver of Preemption; Notice of Decision".
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
H.J. Res. 88, revoking pursuant to the Congressional Review Act California waivers from the Clean Air Act Reform of the definition of the Waters of the United States (WOTUS) under the Clean Water Act
Client expense: — · Firm income: $25,000
Matched citations: H.J. Res. 88
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) Pharmacy benefits management reform Inflation Reduction Act drug price negotiation H.R. 1 (One Big Beautiful Bill Act) provisions related to proposed government drug price controls known as most favored nation being added to the Medicaid or any program H.R. 1 (One Big Beautiful Bill Act) provisions related to Health Savings Account (HSA) reforms Centers for Medicare & Medicaid Services (CMS) Request for Comments on Medicare Drug Price Negotiation Program Draft Guidance, FR Doc. 2025-0860 Reform and eliminate fraud and abuse of the 340B program for pharmaceutical access by providers of indigent care Allowing the Biden-COVID-era Obamacare premium support credits to expire Centers for Medicare & Medicaid Services (CMS) proposed rules, Global Benchmark forEfficient Drug Pricing (GLOBE) for drugs covered under Medicare Part B (Docket No. CMS-2025-1889-0001) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) for drugs covered under Medicare Part D (Docket No. CMS-2025-1888-0001) Elimination of the Center for Medicare and Medicaid Innovation (CMMI) Approval of reauthorization of Floridas Medicaid hospital-directed payment program (DPP) S. 3315 (Health Care Cybersecurity & Resiliency Act) regarding Sen. Bernie Sanderss amendments to codify Most Favored Nation drug price controls
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1
S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1301
More Homes on the Market Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1340
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) Pharmacy benefits management reform Inflation Reduction Act drug price negotiation H.R. 1 (One Big Beautiful Bill Act) provisions related to proposed government drug price controls known as most favored nation being added to the Medicaid or any program H.R. 1 (One Big Beautiful Bill Act) provisions related to Health Savings Account (HSA) reforms Centers for Medicare & Medicaid Services (CMS) Request for Comments on Medicare Drug Price Negotiation Program Draft Guidance, FR Doc. 2025-0860 Reform and eliminate fraud and abuse of the 340B program for pharmaceutical access by providers of indigent care Allowing the Biden-COVID-era Obamacare premium support credits to expire Centers for Medicare & Medicaid Services (CMS) proposed rules, Global Benchmark forEfficient Drug Pricing (GLOBE) for drugs covered under Medicare Part B (Docket No. CMS-2025-1889-0001) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) for drugs covered under Medicare Part D (Docket No. CMS-2025-1888-0001) Elimination of the Center for Medicare and Medicaid Innovation (CMMI) Approval of reauthorization of Floridas Medicaid hospital-directed payment program (DPP) S. 3315 (Health Care Cybersecurity & Resiliency Act) regarding Sen. Bernie Sanderss amendments to codify Most Favored Nation drug price controls
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1492
RESTORE Patent Rights Act of 2025
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1574
Working Families Tax Cut Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 1833
Independent Programmers Tax Incentive Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 2230
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 2794
Patent Eligibility Restoration Act of 2025
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 3152
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 3160
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 3269
H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) S. 527 (Prescription Pricing for the People Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights
Client expense: — · Firm income: $25,000
Matched citations: H.R. 384
Restoring America’s Leadership in Innovation Act of 2025
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 5811
S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 7687
Foreign Anti-Digital Piracy Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 791
American Music Fairness Act of 2025
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: H.R. 861
Providing for consideration of the joint resolution (S.J. Res. 18) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Overdraft Lending: Very Large Financial Institutions"; providing for consideration of the joint resolution (S.J. Res. 28) disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Defining Larger Participants of a Market for General-Use Digital Consumer Payment Applications"; providing for consideration of the bill (H.R. 1526) to amend title 28, United States Code, to limit the authority of district courts to provide injunctive relief, and for other purposes; providing for consideration of the bill (H.R. 22) to amend the National Voter Registration Act of 1993 to require proof of United States citizenship to register an individual to vote in elections for Federal office, and for other purposes; and for other purposes.
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
Executive Order 14192, Unleashing Prosperity Through Deregulation H. Res. 294 provisions related to proxy voting Government shutdown
Client expense: — · Firm income: $25,000
Matched citations: H. Res. 294
Drug Competition Enhancement Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) S. 527 (Prescription Pricing for the People Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights
Client expense: — · Firm income: $25,000
Matched citations: S. 1040
Affordable Prescriptions for Patients Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: S. 1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) S. 527 (Prescription Pricing for the People Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights
Client expense: — · Firm income: $25,000
Matched citations: S. 1096
Interagency Patent Coordination and Improvement Act of 2025
2026 · first_quarter · Firm: ELITE STRATEGIC SERVICES
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: S. 1097
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)
Client expense: — · Firm income: $25,000
Matched citations: S. 1367
Source: Senate LDA